Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals (MIRM) delivers innovative therapies for rare liver diseases through targeted IBAT inhibitor development. This page provides centralized access to official announcements, clinical trial updates, and strategic developments from the biopharmaceutical innovator.
Investors and healthcare professionals will find timely updates on regulatory milestones, partnership agreements, and pipeline advancements. Our curated feed includes verified press releases about Maralixibat approvals, Volixibat trial progress, and corporate initiatives addressing conditions like progressive familial intrahepatic cholestasis.
Key updates cover FDA communications, research collaborations, and commercialization strategies for orphan drug therapies. All content is sourced directly from Mirum’s disclosures to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to Mirum’s latest advancements in minimally absorbed liver disease treatments. Check regularly for critical updates impacting clinical development timelines and therapeutic availability.
Mirum Pharmaceuticals (NASDAQ:MIRM) announced the granting of inducement awards to four new employees under its 2020 Inducement Plan. The awards, approved by the Compensation Committee, include non-qualified stock options to purchase 10,820 shares at $74.89 per share and 5,390 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years, with 33% vesting annually, subject to continued employment.
Mirum Pharmaceuticals (Nasdaq: MIRM) has completed enrollment in its Phase 2b VISTAS study evaluating volixibat, an oral IBAT inhibitor, for treating cholestatic pruritus in primary sclerosing cholangitis (PSC) patients. The trial previously met its pre-specified efficacy and safety thresholds during a blinded interim analysis in 2024.
Topline results from the VISTAS study are expected in Q2 2026. Additionally, volixibat is being evaluated in the Phase 2b VANTAGE study for primary biliary cholangitis (PBC), with enrollment completion expected in 2026 and topline results in H1 2027.
Mirum Pharmaceuticals (NASDAQ:MIRM), a biopharmaceutical company specializing in rare and orphan diseases, has announced its participation in five major investor conferences in September 2025.
The company will present at the Citi Biopharma Back-to-School Summit (Sept 3), Cantor Global Healthcare Conference (Sept 4, 3:20 PM ET), Morgan Stanley Global Healthcare Conference (Sept 8, 8:30 AM ET), Baird Global Healthcare Conference (Sept 9), and H.C. Wainwright Global Investment Conference (Sept 10, 10:00 AM ET). Webcasts will be available through Mirum's corporate website.
Mirum Pharmaceuticals (NASDAQ:MIRM) reported strong Q2 2025 financial results, with total revenue of $128 million, driven by robust commercial performance. The company raised its 2025 revenue guidance to $490-510 million.
LIVMARLI net product sales reached $88.2 million, showing 87% growth year-over-year, while Bile Acid Medicines generated $39.6 million in sales, up 30% from Q2 2024. The company launched LIVMARLI single oral tablet dose in the U.S. in June.
Mirum maintains a strong financial position with $321.7 million in cash and investments. The company's pipeline is advancing with three important late-stage clinical milestones expected in 2026, including the VISTAS study in PSC, VANTAGE study in PBC, and LIVMARLI EXPAND Phase 3 study.
Mirum Pharmaceuticals (NASDAQ:MIRM) has scheduled its second quarter 2025 financial results announcement and conference call for August 6, 2025 at 4:30 p.m. ET. The company will discuss Q2 2025 financial performance and provide updates on recent corporate developments.
Investors can join via phone using U.S. toll-free number +1 833 470 1428 or international number +1 404 975 4839 with access code 448461. A webcast option is available through Mirum's website Events & Presentations section, with replay access for 30 days following the call.
Mirum Pharmaceuticals (NASDAQ:MIRM) announced inducement grants to two new employees under its 2020 Inducement Plan. The compensation package includes 14,460 non-qualified stock options at an exercise price of $53.01 per share and 7,220 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years, with 33% vesting annually, subject to continued employment.
Mirum Pharmaceuticals (Nasdaq: MIRM), a biopharmaceutical company specializing in rare and orphan diseases, has announced its participation in two upcoming investor conferences in May 2025. The company will attend the 3rd Annual H.C. Wainwright BioConnect Investor Conference on May 20th and deliver a company presentation at the RBC Capital Markets Global Healthcare Conference on May 21st at 9:00 AM ET. Interested parties can access webcast links and additional information through the Investors and Media section of Mirum's corporate website.
Mirum Pharmaceuticals (NASDAQ: MIRM) announced inducement awards granted to eight new employees on May 9, 2025. The awards, approved by the Compensation Committee, include:
- Stock options to purchase 53,230 shares at $44.27 per share (closing price on May 9), vesting over 4 years with 25% vesting after one year and remaining monthly over 36 months
- 26,585 restricted stock units (RSUs) vesting over 3 years with 33% vesting annually
The grants were made under Mirum's 2020 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), subject to continued employment.
FAQ
What is the current stock price of Mirum Pharmaceuticals (MIRM)?
What is the market cap of Mirum Pharmaceuticals (MIRM)?
